An interventional study of Preventicus heartbeat app in combination with wearables in Atrial Arrhythmia, sponsored by Atrial Fibrillation Network. Completed at 4 sites in 3 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-07.
Sponsored by Atrial Fibrillation Network · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This feasibility study will develop and evaluate pathways to identify participants with wearable-detected absoulute Arrhythmia (AA) and to enable local study teams to contact them regarding participation in a controlled trial of oral anticoagulation in this population, which will be conducted after the feasibility study.
In this study, the feasibility of evaluating the efficacy of a cloud based analytic service in combination with a PPG-wearable in detecting AA will be assessed and the number of cases found. The design aims to provide simple, low-threshold access to this screening technology targeting at-risk populations. This study will not cause any restrictions on the usual care of the study participants. Access to the screening will be provided close to home and free of charge. The app will also be used to validate and enhance the clinical information about the participants captured during the study. This information will be used to define and refine target groups with highest screening efficiency and, in the long-term, outcome benefits. The study will describe the prevalence of AA in an unselected population that can be reached by a low-threshold screening procedure. The study will also generate important information on the different possible screening environments in different countries (e.g. pharmacies, GP practices, etc). Structures of work-up and continuous patient management in screen-positive individuals will be described and may help to design screening pathways in the main trial. By verifying the wearable-diagnoses by ECG in all screen-positive and a random selection of screen-negative participants, the diagnostic accuracy of the wearable in combination of cloud based analytic service can be estimated. Cost effectiveness assessment will evaluate the cost of low-threshold remote screening per patient identified and help guide to target high risk groups with optimal screening yield in the future. The collected data will provide the sound basis for the design and conduct of a large outcome trial.
Atrial Fibrillation Network is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
Device: Preventicus heartbeat app in combination with wearables
CE certified devices
Proportion of participants with newly detected AA within 4 weeks of device use of all participants included in the study
Proportion of participants with newly detected AA within 4 weeks of device use of all participants included in the study
Time frame: Screening per participant: 4-8 weeks
Propotion of participants with AA detected at any time, including those with AA detected within the full time of recording
Propotion of participants with AA detected at any time, including those with AA detected within the full time of recording
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Time from completed enrolment to the first positive screening, taking death as compeeting risk into account
Time from completed enrolment to the first positive screening, taking death as compeeting risk into account
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Regional differences of AA prevalance (diagnostic yield)
Regional differences of AA prevalance (diagnostic yield)
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Differences by rout fo invitation and enrolment
Differences by rout fo invitation and enrolment
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Duration of atrial arrhythmia episodes
Duration of atrial arrhythmia episodes will be reported descriptively by mean, sd, range, median and IQR
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Follow-up EQ-5DL-5L viscual analogue scale of participants with positve PPG
Follow-up EQ-5DL-5L viscual analogue scale of participants with positve PPG
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Detection of AF: Number of participants with clinically confirmed arrhythmias during Holter ECG
Detection of AF: Number of participants with clinically confirmed arrhythmias during Holter ECG, documented clinically or by event-recorder
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Compliance: The compliance of participants with protocol with regards to the measurement procedure of the app and wearable
Compliance: The compliance of participants with protocol with regards to the measurement procedure of the app and wearable will be presented descriptively
Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months
Ran from Jan 2021 to primary completion in Feb 2022, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atrial Fibrillation Network